Compass Therapeutics (CMPX) filed a registration statement for the potential sale of up to $400 million of securities from time to time.
The shelf covers common and preferred stock, debt securities, warrants, and units, the company said Tuesday in a regulatory filing.
Net proceeds will be used for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.